Industry Assesses Threat From Drug-Pricing Debate
Drug pricing and government oversight were raised as critical issues for the industry in panels, presentations and conversations throughout the BIO CEO & Investor conference, with opinions varying on how much of a threat it could be.
You may also be interested in...
Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.